GSK Pharma Shares Tumble Over 3% as Q2 Revenue Falls Short of Expectations

Headline: GSK Pharma Stock Falls on Lower Q2 Revenue

Details: GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharma) experienced a significant drop in its stock price, falling by over 3% on Friday. This decline followed the company's announcement of lower-than-expected top-line revenue for the second quarter of the current financial year (Q2-FY26). The stock hit an intraday low of ₹2,525.4 per share, marking its second consecutive trading day with a fall exceeding 3%. Overall, the stock had declined 6% over three consecutive sessions, trading at 1.8 times its average 30-day trading volume.

Q2 Results: For the quarter ending September 2025, GlaxoSmithKline Pharmaceuticals reported a net profit of ₹257.49 crore, a modest rise of 1.98% from ₹252.50 crore in the same period last year. However, revenue from operations saw a decline of 3.05%, dropping to ₹979.94 crore from ₹1,010.77 crore a year ago.

Profitability Boost: Despite the revenue dip, the company's EBITDA margin expanded by 250 basis points year-on-year to 34.3%. This improvement was attributed to stable other expenses and lower employee costs. EBITDA itself rose 4.4% year-on-year to ₹330 crore, slightly surpassing the estimate of ₹320 crore.

Reasons for Revenue Impact: The management stated that the topline was affected by two main factors: a fire incident at a major contract manufacturing organisation (CMO) plant and the transition related to the goods and services tax (GST). The company anticipates that operations will begin to stabilize from the second half of FY26, as the fire-related issues have been fully resolved.

Brokerage View (Motilal Oswal): Motilal Oswal Financial Services noted that while revenue missed expectations, EBITDA and net profit were slightly above estimates due to controlled costs and improved profitability. They observed a revenue decline in Q2 and the first half of FY26 after strong growth in the preceding fiscal years. The brokerage maintained its estimates for FY26-FY28, valuing the stock at 38 times 12-month forward earnings, with a target price of ₹2,800. They forecast a 13% compound annual growth rate (CAGR) in earnings over FY25-FY28, expecting stabilization as operational issues resolve and specialty marketing gains traction. A 'Neutral' rating was maintained on the stock.

Impact: The immediate impact on GSK Pharma's stock was negative, with investors reacting to the revenue miss. The company's operational challenges (fire, GST) and subsequent outlook for stabilization will be key monitoring points for investors. The 'Neutral' rating from Motilal Oswal suggests a lack of strong conviction for significant upside or downside in the near term. The pharma sector itself, while generally stable, is sensitive to operational disruptions and regulatory changes.

Impact Rating: 6/10